In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors

Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission

(2012) Nai-Kong V. Cheung et al.   JOURNAL OF CLINICAL ONCOLOGY

Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo

(2012) Nai-Kong V. Cheung et al.   OncoImmunology

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Docking of Carbohydrate Ligands to Antibodies: Structural Validation against Crystal Structures

(2009) Mark Agostino et al.   Journal of Chemical Information and Modeling

Design of therapeutic proteins with enhanced stability

(2009) N. Chennamsetty et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Affinity maturation of antibodies assisted byin silicomodeling

(2008) Rodrigo Barderas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go

(2007) N Moitessier et al.   BRITISH JOURNAL OF PHARMACOLOGY